Physician profile
Dennis Feldman
NPI 1619082369
$7,802.72
in general payments reported to CMS, 2019-2025
32 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,516 · 2020: $1,102 · 2021: $1,407 · 2022: $1,513 · 2023: $1,046 · 2024: $799 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.77 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,081.31 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,302.12 | 2019-2025 | Xifaxan, Trulance |
| Redhill Biopharma INC. | $897.31 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $594.14 | 2019-2025 | |
| Janssen Biotech, INC. | $523.04 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $454.83 | 2019-2024 | Entyvio |
| Pfizer INC. | $269.23 | 2019-2025 | |
| Genzyme Corporation | $188.09 | 2022-2025 | |
| Romark Laboratories, Lc | $186.75 | 2019-2020 | |
| Celgene Corporation | $177.63 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $175.48 | 2022-2024 | Dupixent |
| Allergan, INC. | $160.77 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $140.59 | 2019-2025 | Tremfya |
| Ironwood Pharmaceuticals, INC | $101.93 | 2019-2022 | |
| Lilly USA, LLC | $71.34 | 2023-2024 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $64.94 | 2022 | |
| Intercept Pharmaceuticals, INC. | $50.06 | 2019-2022 | |
| Ardelyx, INC. | $48.18 | 2023-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $42.18 | 2020-2023 | |
| Digestive Care, INC. | $37.50 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $26.74 | 2024 | Bylvay |
| Evoke Pharma, INC. | $25.87 | 2021-2022 | |
| Axonics, INC. | $23.86 | 2023 | Axonics |
| Braintree Laboratories, INC. | $23.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.91 | 2024 | Voquezna |
| Vivus LLC | $20.22 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.64 | 2022 | |
| Daiichi Sankyo INC. | $16.82 | 2019 | |
| Amgen INC. | $15.75 | 2021 | |
| Intra-Sana Laboratories | $14.81 | 2021 | |
| Aimmune Therapeutics, INC. | $14.36 | 2024 | |
| Lucid Diagnostics INC. | $13.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.